Merck Advances Scalable Manufacturing for Oral PCSK9 Therapy

Why It Matters

The ability to produce an oral PCSK9 inhibitor at scale could broaden lipid‑lowering therapy access and shift cardiovascular treatment away from injections, while the biocatalytic method sets a new standard for sustainable peptide manufacturing.

Key Takeaways

• Merck developed scalable biocatalytic synthesis for oral PCSK9 inhibitor enlicitide.
• Process uses engineered enzymes and crystallization purification, reducing chemical waste.
• Oral PCSK9 therapy could improve adherence versus injectable antibodies.
• Biocatalysis platform may accelerate macrocyclic peptide drug development industry-wide.

Pulse Analysis

Oral PCSK9 inhibition has long been a missing piece in cardiovascular care. Current PCSK9 therapies—evolocumab and alirocumab—deliver powerful LDL‑C reductions but require subcutaneous injections, creating adherence hurdles for many patients. As statin‑treated populations still fall short of LDL‑C targets, the market is hungry for a convenient, daily pill that can capture the same mechanistic benefits without the logistical burden of injections. Merck’s enlicitide decanoate aims to fill that gap, promising comparable LDL‑receptor up‑regulation while simplifying the patient experience.

The core of Merck’s announcement is a novel biocatalytic manufacturing platform that replaces traditional, waste‑intensive chemical synthesis with a suite of engineered enzymes. By orchestrating peptide fragment assembly, coupling, and macrocyclization in a single, enzyme‑mediated workflow, the process achieves high stereoselectivity and yields. Crystallization‑based purification further trims downstream processing steps, cutting solvent use and energy consumption. This greener, more efficient approach not only lowers production costs but also aligns with the pharmaceutical industry’s push toward sustainable manufacturing practices.

Beyond enlicitide, the implications for macrocyclic peptide drug development are profound. Macrocyclic peptides can engage protein‑protein interactions that small molecules cannot, yet their complex structures have historically hampered scalable production. Merck’s success demonstrates that biocatalysis can overcome these barriers, offering a template for future oral peptide candidates targeting a range of intracellular and extracellular targets. As competitors race to bring oral biologics to market, the ability to manufacture them sustainably could become a decisive competitive advantage, reshaping pipelines across cardiology, oncology, and beyond.